Genprex Initiates Site Recruitment for Acclaim-1 Clinical Trial for the Treatment of Non-Small Cell Lung CancerBusiness Wire • 11/30/20
Genprex to Participate at the Diamond Equity Research Emerging Growth Invitational on December 1Business Wire • 11/24/20
Genprex Strengthens Scientific Advisory Board with Appointment of Lead Researcher of University of Pittsburgh, George K. Gittes, MDBusiness Wire • 11/10/20
Genprex Unveils New Branding for Upcoming Combination Clinical Trials in Non-Small Cell Lung CancerBusiness Wire • 10/30/20
Genprex Receives Conditional FDA Acceptance of Proprietary Name REQORSA™ for Lead Drug Candidate for Treatment of Non-Small Cell Lung CancerBusiness Wire • 10/29/20
Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the MesaBusiness Wire • 10/06/20
Genprex to Present at Proactive’s One2One Virtual Investor Forum on August 4, 2020Business Wire • 07/31/20
Genprex CEO Participates in a Second-Round Live Interview on the “Big Biz Show”Business Wire • 07/30/20
National Institutes of Health (NIH) Awards Research Grant of $2.59 Million to University of Pittsburgh for Diabetes Gene Therapy Technology Licensed by GenprexBusiness Wire • 07/21/20
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene TherapyBenzinga • 01/21/20
FDA Fast Track on Lung Cancer Treatment Brings Exponential Gains for This Microcap Stock24/7 Wall Street • 01/21/20
Genprex (GNPX) Featured in Audio Publication Discussing New Research on Breast Cancer TreatmentGlobeNewsWire • 09/26/19
Genprex (GNPX) Featured in Publication on Advances in Potential Breast Cancer TreatmentsGlobeNewsWire • 09/25/19
Genprex (GNPX) Featured in NetworkNewsAudio Publication Discussing Lung Cancer and Gene Therapy TreatmentsGlobeNewsWire • 09/06/19
Genprex (GNPX) Featured in NetworkNewsWire Publication Summarizing Gene Therapy Treatment for Lung CancerGlobeNewsWire • 09/05/19
Genprex (GNPX) Featured in Broadcast Discussing Strength, Potential of Biotech SectorGlobeNewsWire • 08/23/19